G-Protein-Coupled Receptors (GPCRs) Function Using cAMP as a Mediator
G-protein-coupled receptors (GPCRs) are the receptor type that typically functions using cAMP as a second messenger, specifically those that couple to Gs proteins to activate adenylyl cyclase.
Mechanism of cAMP-Mediated GPCR Signaling
The fundamental pathway involves Gs-protein coupling that links activated GPCRs to adenylyl cyclase, which catalyzes the conversion of ATP to cyclic AMP (cAMP). 1 This represents the classic second messenger system originally discovered in receptor biology. 2
Key Steps in the Signaling Cascade
Ligand binding to a GPCR activates heterotrimeric G proteins, with the Gs alpha subunit specifically coupling to adenylyl cyclase to stimulate cAMP production. 3 This activation occurs when hormones, autocoids, prostaglandins, or pharmacologic agents bind to their cognate receptors. 2
The generated cAMP then activates protein kinase A (PKA), which phosphorylates numerous downstream signaling proteins and enhances gene transcription. 4 PKA type I localizes to lipid rafts during cell activation and directly modulates proximal signal events. 5
Nine membrane-bound and one soluble adenylyl cyclase isoform exist in mammals, each with distinct regulation and expression patterns. 6 This diversity allows for tissue-specific and context-dependent cAMP signaling.
Major GPCR Classes That Use cAMP
β-Adrenergic Receptors
β2-adrenergic receptors are prototypical Gs-coupled receptors that activate adenylyl cyclase to promote smooth-muscle relaxation through cAMP elevation. 1 This mechanism underlies bronchodilation in asthma treatment with agents like salbutamol and terbutaline. 1, 7
β-adrenergic agonists (dopamine, epinephrine, dobutamine) directly increase cAMP production, leading to enhanced calcium release through ryanodine receptor type 2 (RyR2) channels in cardiac tissue. 7
The β2-adrenergic receptor gene exhibits transcriptional autoregulation through a cAMP response element, creating positive feedback where receptor activation increases its own expression. 8
Prostanoid Receptors
The VPAC1 receptor on platelets is a Gs-coupled receptor that elevates cAMP to inhibit platelet aggregation. 3 This represents an important regulatory mechanism in hemostasis.
Prostacyclin derivatives used to treat pulmonary arterial hypertension work through Gs-coupled receptors to increase cAMP levels. 3
Relaxin Family Peptide Receptors
- RXFP1 (relaxin receptor) couples to adenylyl cyclase via Gs proteins, with relaxin stimulation clearly linked to increased cAMP in multiple tissues including uterus, myometrium, and endometrium. 4 The cAMP increases are important for myometrial inhibition and decidualization of endometrial stromal cells. 4
Proton-Sensing Receptors
- GPR4, GPR65, GPR68, and GPR132 function as proton-sensing GPCRs that display significant constitutive activation of adenylate cyclase through Gs coupling. 4 These receptors detect acidic pH to maintain cellular homeostasis.
Lipid Receptors
- GPR31 binds 12-(S)-HETE and signals through Gs-coupled pathways, while GPR18 responds to N-arachidonoylglycine and inhibits forskolin-induced cAMP production in a pertussis toxin-sensitive manner (indicating Gi coupling). 4
Contrast with Other Signaling Pathways
Gi-Coupled Receptors (Inhibit cAMP)
The ADP receptor P2Y12 and prostaglandin E2 receptor EP3 are Gi-coupled receptors that inhibit adenylyl cyclase, reducing cAMP production. 3 This represents the opposite regulatory mechanism.
RXFP3 receptors couple to Gi to inhibit adenylate cyclase and cAMP accumulation in response to forskolin. 4
Alternative Pathways
The nitric oxide/cGMP pathway activates soluble guanylate cyclase to generate cyclic GMP (cGMP), a distinct relaxation cascade that does not involve adenylyl cyclase or cAMP. 1 This operates parallel to but separate from GPCR-cAMP signaling.
Phosphodiesterase inhibitors (PDE-3 inhibitors like milrinone, inamrinone) increase intracellular cAMP by preventing its breakdown rather than stimulating its synthesis. 1, 7 These work synergistically with β-adrenergic agonists. 7
Clinical Relevance
Alterations in Gs and Gi function are associated with altered cellular reactivity—increased Gs function or defective Gi signaling can be a risk factor for bleeding in platelets, while loss of Gs function results in a prothrombotic state. 3
Many drugs inhibit or stimulate adenylyl cyclase activity through upstream GPCRs (opioid or β-adrenergic receptors), though adenylyl cyclases themselves are emerging as direct drug targets. 6
Increases in intracellular cAMP generally suppress innate immune functions, including inflammatory mediator generation and phagocytosis of microbes. 2 Microbes have evolved virulence strategies that exploit this pathway. 2
GLP-1 receptor agonists that favor cAMP signaling with reduced β-arrestin recruitment maintain glycemic control while potentially reducing gastrointestinal adverse events. 9